Vertex Pharmaceuticals shares are trading higher after the company announced results from Phase 2 study of VX-147 in APOL1-mediated focal segmental glomerulosclerosis.

by | Dec 1, 2021 | Extra Jobs | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.